Simcere’s Sublingual Edaravone Nears International Phase III Trial After China Approval

 
• By Dexter Jie Yan

China’s fresh approval of a sublingual form of Simcere's edaravone/dexborneol brain cytoprotective agent for acute ischemic stroke is paving the way for an international Phase III study in this indication.

stroke.jpg
Sanbexin sublingual significantly improved the ratio of the AIS patients with good functional outcomes by roughly 10 percentage points on day 90.

More from New Products

More from Scrip